Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
3.260
+0.082 (2.58%)
At close: May 12, 2025, 4:00 PM
3.100
-0.160 (-4.91%)
After-hours: May 12, 2025, 5:05 PM EDT
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,600,910
Market Cap
2.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Dec 31, 2023 | 10 | 4 | 66.67% |
| Dec 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
REVB News
- 4 days ago - Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 - Business Wire
- 13 days ago - Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients - Business Wire
- 2 months ago - Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire
- 2 months ago - Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire
- 2 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - Business Wire
- 2 months ago - Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire
- 2 months ago - Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire
- 3 months ago - Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - Business Wire